New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes
2026年6月3日 更新者:Yanbing Li、Sun Yat-sen University
Combination Therapy With Tirzepatide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial
The goal of this clinical trial is to learn the efficacy of combination therapy with tirzepatide, empagliflozin and pioglitazone versus standard therapy in newly diagnosed type 2 diabetes. The main objectives to achieve are:
- To compare efficacy of the triple combination therapy against standard therapy in achieving type 2 diabetes remission in patients newly diagnosed with T2DM.
- To compare the effects on β-cell function and glycemic control of the triple combination therapy against standard therapy in patients newly diagnosed with T2DM Researchers will compare drug new triple combination therapy with tirzepatide, empagliflozin, and pioglitazone to standard therapy (metformin based treatment) to see if new triple combination therapy works better in achieving type 2 diabetes remission.
Participants will:
- Take new triple combination therapy or a standard therapy every day for 6 months
- Visit the clinic once every 0.5-1 month for checkups and tests
- Keep a diary of their fingertip blood glucose and adverse events
研究概览
地位
尚未招聘
条件
研究类型
介入性
注册 (估计的)
296
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Hai Li, MD, PHD
- 电话号码:+86-15920362668
- 邮箱:lihai8@mail.sysu.edu.cn
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- The First Affiliated Hospital of Sun Yat-sen University
-
接触:
- Hai Li, MD, PHD
- 电话号码:+86-15920362668
- 邮箱:lihai8@mail.sysu.edu.cn
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Male or female, 18 years≤age≤75 years at the time of signing informed consent.
- Newly diagnosed with type 2 diabetes, or diagnosed within 1 years according to the WHO diagnostic criteria.
- Individuals who had not received previous antidiabetic therapy, or had not received antidiabetic therapy within 3 months prior to screening, or had not received antidiabetic therapy for more than 3 consecutive months or a combined total of more than 3 months in the past 2 years.
- 6.5%≤HbA1c≤9.0% at screening confirmed by central laboratory analysis.
- BMI≥24 kg/m2.
Exclusion Criteria:
- Individuals with type 1 diabetes or special types of diabetes.
- Allergy or intolerance to investigational drugs.
- Estimated Glomerular Filtration Rate (eGFR) <20 mL/min/1.73 m².
- Individuals with heart failure in New York Heart Association [NYHA] class III or IV in the 6 months prior to randomization.
- History of bladder cancer or hematuria.
- History of Multiple Endocrine Neoplasia Type 2 (MEN 2) or relevant family history.
- History or family history of Medullary Thyroid Carcinoma (MTC), or susceptibility to MTC due to hereditary conditions.
- History of fasting blood glucose≥13.9 mmol/L or the necessity for insulin use due to severe infection, diabetic foot, etc.
- History of acute diabetic complications: including diabetic ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis.
- Severe diabetic microvascular complications: proliferative retinopathy, or urinary AER>300mg/g, or urinary protein positive, quantitative >0.5g/24h.
- Uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy.
- Severe diabetic macrovascular complications: myocardial infarction, stroke or hospitalization for unstable angina and/or transient ischemic attack and/or peripheral arterial disease required for vascular intervention or amputation within the 12 months prior to screening.
- Blood pressure persistently higher than 180/110 mmHg and not controllable to ≤160/100 mmHg within 1 week.
- Alanine Aminotransferase (ALT) ≥2.5 times the upper normal limit, total bilirubin ≥1.5 times the upper normal limit.
- Hemoglobin <100g/L or requiring regular blood transfusion.
- Use of medicines potentially affecting blood glucose for more than 1 week cumulatively in the past 12 weeks, such as corticosteroids, growth hormone analogs, estrogen/progestogen, high-dose diuretics, antipsychotic drugs, etc.
- Participation in another trial involving medicine therapy within the past 3 months.
- Expected lifespan less than 2 years as per the investigator's clinical judgment, e.g., but not limited to malignancy.
- Pregnant or lactating females, or females of childbearing potential who cannot or are unwilling to use adequate contraception.
- Deemed unsuitable for participation in this clinical trial at the discretion of the investigator.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group A (triple combination intensive therapy group)
Tirzepatide, empagliflozin, and pioglitazone treatment.
1) Initiate with Tirzepatide 2.5 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, adjust Tirzepatide to 5.0 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd; 3) After 1 month, adjust Tirzepatide to 7.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd.
4) After 1 month, adjust Tirzepatide to 10.0 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd; 5) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
|
1) Initiate with Tirzepatide 2.5 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, adjust Tirzepatide to 5.0 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd; 3) After 1 month, adjust Tirzepatide to 7.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd.
4) After 1 month, adjust Tirzepatide to 10.0 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd; 5) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
|
|
有源比较器:Group B (standard therapy group)
Metformin-based treatment is recommended when not contraindicated.
1) Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After 1 month, if blood glucose remains uncontrolled, add Tirzepatide 2.5 mg qw; 4) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 5.0 mg qw; 5) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 7.5 mg qw; 6) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 10.0 mg qw.
|
1) Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After 1 month, if blood glucose remains uncontrolled, add Tirzepatide 2.5 mg qw; 4) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 5.0 mg qw; 5) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 7.5 mg qw; 6) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 10.0 mg qw.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
糖尿病缓解率
大体时间:停用药物后6个月
|
停用药物后6个月的糖尿病缓解率(在停药后6个月的HBA1C患者百分比<6.5%)
|
停用药物后6个月
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
糖尿病缓解率
大体时间:停药后3和12个月
|
药物停用后3和12个月的糖尿病缓解率和糖尿病缓解时间
|
停药后3和12个月
|
|
EQ-5D-5L问卷调查,生活质量
大体时间:在基线时,在药物治疗的6个月时,在停用药物后3、6和12个月
|
EQ-5D-5L问卷调查,评估生活质量。 EQ-5D-5L基本上由2页组成:EQ-5D描述系统和EQ Visual模拟量表(EQ VAS)。 描述性系统包括五个维度:流动性,自我保健,通常的活动,疼痛/不适和焦虑/抑郁。 每个维度有5个级别:没有问题,小问题,中度问题,严重的问题和极端问题。 EQ VAS以垂直视觉模拟量表记录了患者的自我评估健康状况,其中端点被标记为“您可以想象的最佳健康”和“您能想象的最糟糕的健康”。 VA可以用作反映患者自身判断的健康结果的定量度量。 |
在基线时,在药物治疗的6个月时,在停用药物后3、6和12个月
|
|
每次缓解的增量成本
大体时间:停用药物后6个月
|
停用药物后6个月的每次缓解费用增加
|
停用药物后6个月
|
|
范围(TIR)的时间
大体时间:在基线时,在6个月的药物治疗中,在停用药物后6个月
|
目标血糖范围内的时间(3.9-10.0
mmol/l)
|
在基线时,在6个月的药物治疗中,在停用药物后6个月
|
|
每次额外改善范围(TIR)的增加成本(TIR)
大体时间:6个月的药物治疗,并在停用药物后6个月
|
在药物治疗的6个月后,在停用药物后6个月,每次额外改善范围(TIR)的额外成本增加
|
6个月的药物治疗,并在停用药物后6个月
|
|
Time required to achieve glycemic goal
大体时间:6 months of medication
|
The time required to achieve glycemic goal(FBG <6.1mmol/L, 2h PPG <8.0mmol/L or HbA1c#6.5%)
|
6 months of medication
|
|
HbA1c
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
HbA1c level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Blood glucose level
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
Fasting and 2-hour postprandial blood glucose level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Blood insulin level
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
Fasting and 2-hour postprandial insulin level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Blood C-peptide level
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
Fasting and 2-hour postprandial C-peptide level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Pancreatic β-cell function
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
HOMA-B at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Insulin resistance
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
HOMA-IR at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Weight changes
大体时间:At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
Weight at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
|
|
Incremental cost per QALY gained
大体时间:At baseline, at 6 months of medication treatment, and at 3, 6, and 12 months after discontinuation of medication
|
Incremental cost per QALY gained, derived from EQ-5D-5L assessments at baseline, at 6 months of medication treatment, and at 3, 6, and 12 months after discontinuation of medication
|
At baseline, at 6 months of medication treatment, and at 3, 6, and 12 months after discontinuation of medication
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月1日
初级完成 (估计的)
2029年7月1日
研究完成 (估计的)
2031年7月1日
研究注册日期
首次提交
2026年6月3日
首先提交符合 QC 标准的
2026年6月3日
首次发布 (实际的)
2026年6月9日
研究记录更新
最后更新发布 (实际的)
2026年6月9日
上次提交的符合 QC 标准的更新
2026年6月3日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.